These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16123677)

  • 21. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
    Martinson NA; Morris L; Gray G; Moodley D; Pillay V; Cohen S; Dhlamini P; Puren A; Bhayroo S; Steyn J; McIntyre JA
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):148-53. PubMed ID: 17117145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
    Eshleman SH; Becker-Pergola G; Deseyve M; Guay LA; Mracna M; Fleming T; Cunningham S; Musoke P; Mmiro F; Jackson JB
    J Infect Dis; 2001 Oct; 184(7):914-7. PubMed ID: 11509999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    Toni TD; Masquelier B; Lazaro E; Dore-Mbami M; Ba-Gomis FO; Téa-Diop Y; Kouakou K; Diby J; Sia E; Soppi S; Essien S; Schrive MH; Pinson P; Chenal H; Fleury HJ
    AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1031-4. PubMed ID: 16379606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
    Basson AE; Ntsala M; Martinson N; Tlale E; Corrigan GE; Shao X; Gray G; McIntyre J; Puren A; Morris L
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):538-43. PubMed ID: 18989222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
    Martinson NA; Morris L; Johnson J; Gray GE; Pillay V; Ledwaba J; Dhlamini P; Cohen S; Puren A; Steyn J; Heneine W; McIntyre JA
    AIDS; 2009 Apr; 23(7):809-16. PubMed ID: 19287298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.
    Lalonde MS; Troyer RM; Syed AR; Bulime S; Demers K; Bajunirwe F; Arts EJ
    J Clin Microbiol; 2007 Aug; 45(8):2604-15. PubMed ID: 17567789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
    Flys TS; McConnell MS; Matovu F; Church JD; Bagenda D; Khaki L; Bakaki P; Thigpen MC; Eure C; Fowler MG; Eshleman SH
    J Infect Dis; 2008 Aug; 198(4):465-9. PubMed ID: 18582198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
    AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nevirapine resistance after single dose prophylaxis.
    Eshleman SH; Jackson JB
    AIDS Rev; 2002; 4(2):59-63. PubMed ID: 12152519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
    Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.
    Hauser A; Mugenyi K; Kabasinguzi R; Kuecherer C; Harms G; Kunz A
    PLoS One; 2011; 6(5):e20357. PubMed ID: 21655245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
    J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
    Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
    Loubser S; Balfe P; Sherman G; Hammer S; Kuhn L; Morris L
    AIDS; 2006 Apr; 20(7):995-1002. PubMed ID: 16603851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
    Kassaye S; Lee E; Kantor R; Johnston E; Winters M; Zijenah L; Mateta P; Katzenstein D
    AIDS Res Hum Retroviruses; 2007 Aug; 23(8):1055-61. PubMed ID: 17725424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
    Hudelson SE; McConnell MS; Bagenda D; Piwowar-Manning E; Parsons TL; Nolan ML; Bakaki PM; Thigpen MC; Mubiru M; Fowler MG; Eshleman SH
    AIDS; 2010 Feb; 24(4):557-61. PubMed ID: 20057308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Chaix ML; Ekouevi DK; Peytavin G; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Amani-Bosse C; Menan H; Leroy V; Rouzioux C; Dabis F
    Antimicrob Agents Chemother; 2007 Mar; 51(3):896-901. PubMed ID: 17178792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.
    Wu H; Zhang HJ; Zhang XM; Xu HF; Wang M; Huang JD; Zheng BJ
    PLoS One; 2012; 7(9):e44333. PubMed ID: 22984494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
    Pilger D; Hauser A; Kuecherer C; Mugenyi K; Kabasinguzi R; Somogyi S; Harms G; Kunz A
    Antivir Ther; 2011; 16(1):109-13. PubMed ID: 21311114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.